ログイン
ランキング
お知らせ
ログイン
文献詳細
特集 分子を撃つ 神経疾患治療の新しい水平線
文献概要
エクリズマブは，遺伝子組換えヒト化モノクローナル抗体で，終末補体であるC5と特異的に結合し，補体活性化を介したC5からC5aやC5bへの開裂反応を阻害する。発作性夜間ヘモグロビン尿症における溶血抑制を適応症として，すでに臨床応用されている。神経疾患に対しては，病態に補体が介在することが明らかになっている視神経脊髄炎や重症筋無力症への治験が始まっており，難治性神経疾患に対する治療薬としても期待されている。
参考文献
1) Russell RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L: Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25: 1256-1264, 2007
2) Rus HG, Niculescu FI, Shin ML: Role of the C5b-9 complement complex in cell cycle and apoptosis. Immunol Rev 180: 49-55, 2001
3) Jack DL, Klein NJ, Turner MW: Mannose-binding lectin: targeting the microbial world for complement attack and opsonophagocytosis. Immunol Rev 180: 86-99, 2001
4) Yamashina M, Ueda E, Kinoshita T, Takami T, Ojima A, et al: Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med 323: 1184-1189, 1990
5) Motoyama N, Okada N, Yamashina M, Okada H: Paroxysmal nocturnal hemoglobinuria due to hereditary nucleotide deletion in the HRF20 (CD59) gene. Eur J Immunol 22: 2669-2673, 1992
6) Parker C, Omine M, Richards S, Nishimura J, Bessler M, et al: Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 106: 3699-3709, 2005
7) Richards SJ, Rawstron AC, Hillmen P: Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry 42: 223-233, 2000
8) Hill DA, Wang SS, Cerhan JR, Davis S, Cozen W, et al: Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes. Blood 108: 3161-3167, 2006
9) Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, et al: Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 350: 552-559, 2004
10) Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, et al: Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial. Int J Hematol 93: 36-46, 2011
11) Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, et al: The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355: 1233-1243, 2006
12) Benz K, Amann K: Thrombotic microangiopathy: new insights. Curr Opin Nephrol Hypertens 19: 242-247, 2010
13) Noris M, Remuzzi G: Atypical hemolytic-uremic syndrome. N Engl J Med 361: 1676-1687, 2009
14) Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, et al: Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5: 1844-1859, 2010
15) Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, et al: Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108: 1267-1279, 2006
16) Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, et al: Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368: 2169-2181, 2013
17) Jacob A, McKeon A, Nakashima I, Sato DK, Elsone L, et al: Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry 84: 922-930, 2013
18) Fujihara K: Neuromyelitis optica and astrocytic damage in its pathogenesis. J Neurol Sci 306: 183-187, 2011
19) Wingerchuk DM, Weinshenker BG: Neuromyelitis optica. Curr Treat Options Neurol 10: 55-66, 2008
20) Kitley J, Leite MI, Nakashima I, Waters P, McNeillis B, et al: Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 135: 1834-1849, 2012
21) Kimbrough DJ, Fujihara K, Jacob A, Lana-Peixoto MA, Leite MI, et al: Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord 1: 180-187, 2012
22) Miyamoto K, Kusunoki S: Intermittent plasmapheresis prevents recurrence in neuromyelitis optica. Ther Apher Dial 13: 505-508, 2009
23) Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, et al: Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 82: 1302-1306, 2014
24) Conti-Fine BM, Milani M, Kaminski HJ: Myasthenia gravis: past, present, and future. J Clin Invest 116: 2843-2854, 2006
25) Tüzün E, Huda R, Christadoss P: Complement and cytokine based therapeutic strategies in myasthenia gravis. J Autoimmun 37: 136-143, 2011
26) 日本神経学会（監), 「重症筋無力症診療ガイドライン」作成委員会: 重症筋無力症診療ガイドライン2014．南江堂, 東京, 2014
27) Shiraishi H, Motomura M, Yoshimura T, Fukudome T, Fukuda T, et al: Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 57: 289-293, 2005
28) Hinson SR, Romero MF, Popescu BF, Lucchinetti CF, Fryer JP, et al: Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Nat Acad Sci U S A 109: 1245-1250, 2012
29) Tüzün E, Kürtüncü M, Türkoğlu R, Içöz S, Pehlivan M, et al: Enhanced complement consumption in neuromyelitis optica and Behcet's disease patients. J Neuroimmunol 233: 211-215, 2011
30) Kuroda H, Fujihara K, Takano R, Takai Y, Takahashi T, et al: Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica. J Neuroimmunol 254: 178-182, 2013
31) Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, et al: Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 12: 554-562, 2013
32) Howard JF Jr, Barohn RJ, Cutter GR, Freimer M, Juel VC, et al: A randomized, double-blind, p lacebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve 48: 76-84, 2013
33) Hillmen P, Elebute M, Kelly R, Urbano-Ispizua A, Hill A, et al: Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol 85: 553-559, 2010
34) Kelly R, Arnold L, Richards S, Hill A, Bomken C, et al: The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol 149: 446-450, 2010
掲載誌情報
